Creatine Prodrugs Enhance Brain Uptake and Energy Homeostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current creatine supplementation for treating creatine transporter defects is limited by high doses required to overcome gastrointestinal absorption and brain uptake barriers, leading to adverse effects and incomplete therapeutic efficacy due to reliance on the creatine transporter.
Innovation Solution
Development of creatine prodrugs that can pass through biological membranes, including the blood-brain barrier, by either passive diffusion or active transport independently of the creatine transporter, allowing for sustained systemic concentrations and enhanced therapeutic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of creatine are administered to overcome gastrointestinal absorption and brain uptake barriers, then therapeutic efficacy is improved, but adverse effects increase
Solution Approach 1:
The patent changes the chemical parameters of creatine by converting it into prodrug forms (e.g., creatine esters, creatine amides, creatine carbamates) with modified molecular structures. These prodrugs have improved lipophilicity and membrane permeability properties, allowing them to cross the blood-brain barrier and gastrointestinal barriers more efficiently at lower doses, thereby maintaining therapeutic efficacy while reducing adverse effects associated with high-dose creatine administration
Solution Approach 2:
The patent introduces prodrug molecules as intermediary compounds that serve as carriers for creatine delivery. These prodrugs act as mediators between the administered creatine and the target tissues (brain and skeletal muscle), facilitating transport across biological barriers through passive diffusion or alternative transport mechanisms, thus improving bioavailability and reducing the need for high dosing
2Reliability
If traditional creatine supplementation is used for treating creatine transporter defects, then some therapeutic benefit is achieved, but brain uptake is incomplete due to reliance on the creatine transporter
Solution Approach 1:
The patent employs prodrug molecules as intermediary carriers that bypass the defective creatine transporter system. These prodrugs utilize alternative transport mechanisms (passive diffusion, amino acid transporters, or other non-specific transport pathways) to deliver creatine equivalents into the brain, thereby compensating for the incomplete brain uptake caused by creatine transporter defects and achieving more complete therapeutic coverage
Solution Approach 2:
Instead of attempting to improve the function of the defective creatine transporter, the patent inverts the approach by using prodrugs that enter the brain through alternative pathways. This inverse strategy avoids the defective transporter system entirely, using different molecular structures that can utilize other available transport mechanisms to achieve brain penetration
3Quantity of substance
If high doses of creatine are administered to achieve effective treatment, then therapeutic concentrations are reached, but gastrointestinal disorders and nitrogen exchange disturbance occur
Solution Approach 1:
The patent modifies the chemical parameters of creatine by creating prodrugs with altered solubility, stability, and absorption characteristics. These prodrug forms (esters, amides, carbamates) exhibit improved gastrointestinal tolerance and reduced metabolic burden, allowing achievement of therapeutic concentrations in target tissues without causing gastrointestinal disorders or nitrogen exchange disturbance associated with high-dose creatine
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The creatine prodrugs effectively restore and maintain energy homeostasis in ATP-depleted cells, providing rapid ATP level restoration and improved tissue protection against ischemic stress, with reduced adverse effects and improved brain uptake compared to traditional creatine supplementation.
Implementation Method 1
pass through biological membranes, including the blood-brain barrier, by either passive diffusion or active transport independently of the creatine transporter
Implementation Method 2
pass through biological membranes, including the blood-brain barrier, by either passive diffusion or active transport independently of the creatine transporter
Implementation Method 3
Creatine, when phosphorylated by creatine kinase with an adenosine triphosphate (ATP), forms a high-energy phosphocreatine (creatine phosphate), which is a significant cellular energy reserve
Implementation Method 4
Creatine, when phosphorylated by creatine kinase with an adenosine triphosphate (ATP), forms a high-energy phosphocreatine (creatine phosphate)
Implementation Method 5
The level of phosphocreatine in a cell is an important predictor of resistance to ischemic insult, and remaining stores of creatine phosphate are correlated with the extent of tissue damage
Data Source
AI summary
The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.